BAFF-R-CAR T cells with a 4-1BB costimulatory signaling domain demonstrated therapeutic effects against CD19 negative B-cell ALL in vitro and in vivo (117), and are currently undergoing clinical trials for the treatment of adult ALL (NCT04690595). Here, CD19 is linked to acute lymphoblastic leukemia.